Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kestra Medical Technologies (KMTS) EBITDA Margin (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed EBITDA Margin for 3 consecutive years, with 141.6% as the latest value for Q1 2026.

  • Quarterly EBITDA Margin fell 508.0% to 141.6% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 171.53% through Jan 2026, down 2237.0% year-over-year, with the annual reading at 177.85% for FY2025, 12798.0% up from the prior year.
  • EBITDA Margin for Q1 2026 was 141.6% at Kestra Medical Technologies, down from 140.73% in the prior quarter.
  • The five-year high for EBITDA Margin was 130.07% in Q4 2024, with the low at 279.77% in Q2 2025.
  • Average EBITDA Margin over 3 years is 173.93%, with a median of 144.19% recorded in 2024.
  • Peak annual rise in EBITDA Margin hit 10446bps in 2025, while the deepest fall reached -7737bps in 2025.
  • Over 3 years, EBITDA Margin stood at 130.07% in 2024, then fell by -8bps to 140.73% in 2025, then fell by -1bps to 141.6% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 141.6%, 140.73%, and 149.08% for Q1 2026, Q4 2025, and Q3 2025 respectively.